ANF Stock Analysis: Abercrombie & Fitch | NYSE
Apparel Retail | NYSE, USA | Market Cap: 5.767m USD | 12M Return: 85.4% | US0028962076 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 163M
EPS Trend: 69.3%
Qual. Beats: 2
Rev. Trend: 95.4%
Qual. Beats: 1
Warnings
No concerns identified
Tailwinds
Seasonality 11.7 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Abercrombie & Fitch Co. (NYSE: ANF) is a U.S.-based omnichannel apparel retailer that sells mens, womens, and kids clothing, personal care products, and accessories under five owned brands: Abercrombie & Fitch, abercrombie kids, Your Personal Best, Hollister, and Gilly Hicks. The company distributes through a mix of company-operated stores, e-commerce sites, wholesale accounts, franchise partners, and licensing arrangements, giving it direct-to-consumer reach alongside lower-capital revenue streams. Founded in 1892 and headquartered in New Albany, Ohio, ANF has been publicly traded since 1996 and is classified in the Consumer Discretionary sector under Apparel Retail.
As an Apparel Retail operator, ANFs results are tied to discretionary consumer spending and seasonal demand cycles, and its multi-brand portfolio is a common strategy in the sector for targeting different age and lifestyle segments. Licensing arrangements, in particular, allow apparel retailers to extend brand reach into categories such as fragrances and accessories without the capital costs of vertical manufacturing.
- Hollister comparable sales momentum drives quarterly revenue beats
- A&F brand turnaround fuels operating margin expansion above guidance
- Tariff exposure on Asia-sourced apparel pressures gross margins
- International segment expansion in EMEA and Asia-Pacific accelerates top-line growth
| Net Income: 536.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.16 > 0.02 and ΔFCF/TA 5.31 > 1.0 |
| NWC/Revenue: 8.37% < 20% (prev 8.85%; Δ -0.48% < -1%) |
| CFO/TA 0.23 > 3% & CFO 819.6m > Net Income 536.0m |
| Net Debt (649.4m) to EBITDA (924.4m): 0.70 < 3 |
| Current Ratio: 1.41 > 1.5 & < 3 |
| Outstanding Shares: last quarter (44.1m) vs 12m ago -9.27% < -2% |
| Gross Margin: 62.88% > 18% (prev 62.71%; Δ 0.17% > 0.5%) |
| Asset Turnover: 154.9% > 50% (prev 154.4%; Δ 0.43% > 0%) |
| Interest Coverage Ratio: 361.0 > 6 (EBIT TTM 759.8m / Interest Expense TTM 2.10m) |
| A: 0.12 (Total Current Assets 1.55b - Total Current Liabilities 1.10b) / Total Assets 3.59b |
| B: 1.10 (Retained Earnings 3.94b / Total Assets 3.59b) |
| C: 0.22 (EBIT TTM 759.8m / Avg Total Assets 3.45b) |
| D: 0.61 (Book Value of Equity 1.35b / Total Liabilities 2.23b) |
| Altman-Z'' = 6.51 = AAA |
| DSRI: 1.04 (Receivables 190.3m/174.0m, Revenue 5.34b/5.10b) |
| GMI: 1.00 (GM 62.71% / 62.88%) |
| AQI: 0.89 (AQ_t 0.06 / AQ_t-1 0.07) |
| SGI: 1.05 (Revenue 5.34b / 5.10b) |
| TATA: -0.08 (NI 536.0m - CFO 819.6m) / TA 3.59b) |
| Beneish M = -3.03 (Cap -4..+1) = AA |
As of October 11, 2026, the stock is trading at USD 142.58 with a total of 1,002,037 shares traded. Over the past week, the price has changed by +4.91%, over one month by -6.25%, over three months by +59.79% and over the past year by +85.39%.
Current recommended Stop Loss: 128.70 (which is 9.7% or 2.6 ATR below the current price).
Abercrombie & Fitch has received a consensus analysts rating of 4.00. Therefore, it is recommended to buy ANF.
- StrongBuy: 7
- Buy: 1
- Hold: 7
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 163.6 | 14.7% |
P/E Trailing = 11.7366
P/E Forward = 10.02
P/S = 1.0798
P/B = 4.1431
P/EG = 3.6242
Revenue TTM = 5.34b USD
EBIT TTM = 759.8m USD
EBITDA TTM = 924.4m USD
Long Term Debt = 1.03b USD (estimated: total debt 1.29b - short term 262.4m)
Short Term Debt = 262.4m USD (from shortTermDebt, last quarter)
Debt = 1.29b USD (from shortLongTermDebtTotal, last quarter) (leases 1.29b already included)
Net Debt = 649.4m USD (calculated: Debt 1.29b - CCE 638.0m)
Enterprise Value = 6.42b USD (5.77b + Debt 1.29b - CCE 638.0m)
Interest Coverage Ratio = 361.0 (Ebit TTM 759.8m / Interest Expense TTM 2.10m)
EV/FCF = 11.33x (Enterprise Value 6.42b / FCF TTM 566.5m)
FCF Yield = 8.83% (FCF TTM 566.5m / Enterprise Value 6.42b)
FCF Margin = 10.61% (FCF TTM 566.5m / Revenue TTM 5.34b)
Net Margin = 10.04% (Net Income TTM 536.0m / Revenue TTM 5.34b)
Gross Margin = 62.88% ((Revenue TTM 5.34b - Cost of Revenue TTM 1.98b) / Revenue TTM)
Gross Margin QoQ = 71.10% (prev 59.05%)
Tobins Q-Ratio = 1.78 (Enterprise Value 6.42b / Total Assets 3.59b)
Interest Expense / Debt = 0.16% (Interest Expense 2.10m / Debt 1.29b)
Taxrate = 28.27% (214.2m / 757.7m)
NOPAT = 545.0m (EBIT 759.8m * (1 - 28.27%))
Current Ratio = 1.41 (Total Current Assets 1.55b / Total Current Liabilities 1.10b)
Debt / Equity = 0.95 (Debt 1.29b / totalStockholderEquity, last quarter 1.35b)
Debt / EBITDA = 0.70 (Net Debt 649.4m / EBITDA 924.4m)
Debt / FCF = 1.15 (Net Debt 649.4m / FCF TTM 566.5m)
Total Stockholder Equity = 1.35b (last 4 quarters mean from totalStockholderEquity)
RoA = 15.54% (Net Income 536.0m / Total Assets 3.59b)
RoE = 39.59% (Net Income TTM 536.0m / Total Stockholder Equity 1.35b)
RoCE = 31.94% (EBIT 759.8m / Capital Employed (Equity 1.35b + L.T.Debt 1.03b))
RoIC = 21.88% (NOPAT 545.0m / Invested Capital 2.49b)
WACC = 7.99% (E(5.77b)/V(7.05b) * Re(9.75%) + D(1.29b)/V(7.05b) * Rd(0.16%) * (1-Tc(0.28)))
Discount Rate = 9.75% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -97.97 | Cagr: -8.10%
[DCF] Terminal Value 77.97% ; FCFF base≈477.9m ; Y1≈547.8m ; Y5≈806.2m
[DCF] Fair Price = 270.6 (EV 12.1b - Net Debt 649.4m = Equity 11.5b / Shares 42.4m; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: 69.28 | EPS CAGR: 24.27% | SUE: 3.38 | # QB: 2
Revenue Correlation: 95.44 | Revenue CAGR: 10.08% | SUE: 1.14 | # QB: 1
EPS current Quarter (2026-10-31): EPS=3.11 | Chg30d=+7.51% | Revisions=+50% | Analysts=6
EPS current Year (2027-01-31): EPS=13.54 | Chg30d=+26.30% | Revisions=+62% | GrowthEPS=+29.5% | GrowthRev=+5.0%
EPS next Year (2028-01-31): EPS=13.18 | Chg30d=+11.13% | Revisions=+38% | GrowthEPS=-2.7% | GrowthRev=+4.3%
[Analyst] Revisions Ratio: +69% (up=12, down=1)